M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project PharmaTimesPartnership grants Lilly global rights to Alzstatin ACD680NeuroscienceRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) PharmaTimes Partnership grants Lilly global rights to Alzstatin ACD680 Neuroscience Read full story Post navigation Previous: ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill dataNext: Cancer biotech Parabilis books record IPO, raising $670m Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
